1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Biotechnology
4basebio PLC

4basebio PLC

525.00
GBX
0.00
(0.00%)
9.52BMarket Cap
Jun 02Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.02
0.04
0.03
0.02
0.04
0.07
0.11
- -
Basic EPS, GAAP
-0.03
-0.06
-0.26
-0.42
-0.62
-0.94
-1.09
- -
Free Cash Flow per Basic Share
-0.02
-0.11
-0.29
-0.48
-0.57
-0.87
-1.04
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.15
1.25
0.95
0.58
-0.04
1.71
0.65
0.65
Tangible Book Value per Share
-0.19
1.19
0.85
0.41
-0.26
1.48
0.34
0.34
Basic Weighted Avg Shares
12
12
12
12
12
13
16
16
Sales/Revenue/Turnover
- -
- -
- -
- -
1
1
2
- -
Operating Margin (%)
-207.92
-134.63
-943.2
-2,115.3
-1,613.83
-1,371.17
-984.29
- -
Depreciation Expense
- -
- -
- -
- -
1
1
1
- -
Net Income, GAAP
- -
-1
-3
-5
-8
-12
-17
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-209.41
-155.63
-957.1
-1,921.64
-1,514.82
-1,321.86
-998.52
- -
Working Capital
- -
15
9
4
3
34
18
18
LT Debt
2
1
1
3
10
15
17
17
Total Equity
-2
15
12
7
- -
26
10
10
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-23.83
-54.74
- -
- -
-92.65
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
14
- -
16
LT Finance Leases
1
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
187
153
95

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
37
29
21
Cash, Cash Equivalents & STI
35
26
18
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
1
1
Total Current Liabilities
3
3
3
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-1,138.77%
-61.67%
Free Cash Flow
- -
69.72%
40.35%
Net Income, GAAP
- -
111.19%
37.07%
Sales/Revenue/Turnover
- -
41.42%
81.46%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1
2024
- -
- -
1
2025
- -
- -
2

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.62
2024
- -
- -
-0.94
2025
- -
- -
-1.09

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Amy Jo Walker
Full Time Employees
140
Sector
Health technology
Industry
Biotechnology
Address
25 Norman Way Cambridge CAM United Kingdom CB24 5QE
IPO Date
Feb 17, 2021
Website
4basebio.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
4basebio PLC (AIM: 4BB.L), a Cambridge, United Kingdom-based biotechnology company founded in 2008, develops and manufactures synthetic DNA and RNA products alongside non-viral nucleic acid delivery platforms to accelerate advanced therapy medicinal products including gene therapies, mRNA vaccines and therapeutics, viral vectors, genome editing tools, and DNA vaccines; its core offerings encompass GMP-grade opDNA synthetic DNA templates produced via a proprietary enzymatic cell-free process using TruePrime amplification technology, application-specific dsDNA and ssDNA constructs, custom pegRNA and mRNA synthesis services, RUO-grade off-the-shelf mRNA for reporter genes, and the Hermes targeted non-viral delivery platform featuring thermostable nanoparticles for efficient payload delivery surpassing conventional LNPs. The company serves biopharma, academic, and research clients globally with operations centered in the UK, emphasizing superior speed (up to 4x faster than plasmid DNA), purity, scalability, and safety by eliminating bacterial sequences. Recent developments include securing MHRA GMP manufacturing license in April 2025 enabling clinical-grade DNA supply, completing a £40 million strategic equity investment from Elevage Medical Technologies and M&G Investment Management in November 2024, achieving revenue growth to £1.2 million in H1 2025 (nearly 4x YoY) with opDNA powering a tier-1 pharma's FDA IND-approved mRNA vaccine and partnerships like HelixNano, introducing refreshed branding and website in July 2025, participating in a £1.2 million UK-Canada consortium for influenza vaccine development in July 2025, expanding its IP portfolio to 31 patent families, and scaling commercial teams to target late preclinical and IND-stage clients.